Equities research analysts expect Genomic Health, Inc. (NASDAQ:GHDX) to post earnings per share (EPS) of $0.31 for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Genomic Health’s earnings. The lowest EPS estimate is $0.30 and the highest is $0.33. Genomic Health reported earnings per share of $0.08 in the same quarter last year, which suggests a positive year over year growth rate of 287.5%. The firm is expected to announce its next earnings results on Thursday, March 14th.

On average, analysts expect that Genomic Health will report full-year earnings of $1.06 per share for the current financial year, with EPS estimates ranging from $1.04 to $1.07. For the next year, analysts expect that the firm will post earnings of $1.23 per share, with EPS estimates ranging from $1.04 to $1.55. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Genomic Health.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.28. The firm had revenue of $101.30 million during the quarter, compared to the consensus estimate of $94.27 million. Genomic Health had a return on equity of 14.05% and a net margin of 4.95%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.06) earnings per share.

Several analysts recently weighed in on GHDX shares. Raymond James assumed coverage on Genomic Health in a report on Tuesday, October 23rd. They issued a “market perform” rating for the company. Zacks Investment Research upgraded Genomic Health from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a research note on Monday, August 6th. BidaskClub upgraded Genomic Health from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 30th. Piper Jaffray Companies lifted their target price on Genomic Health from $34.00 to $50.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. Finally, Canaccord Genuity lifted their target price on Genomic Health from $56.00 to $62.00 and gave the company a “buy” rating in a research note on Friday, August 3rd. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $48.33.

In other news, Director Bros. Advisors Lp Baker sold 204,300 shares of the business’s stock in a transaction dated Tuesday, November 13th. The stock was sold at an average price of $79.33, for a total transaction of $16,207,119.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kimberly J. Popovits sold 50,000 shares of the business’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $65.28, for a total value of $3,264,000.00. The disclosure for this sale can be found here. Insiders have sold 545,394 shares of company stock worth $42,271,195 in the last 90 days. Insiders own 45.80% of the company’s stock.

Several hedge funds have recently modified their holdings of GHDX. Globeflex Capital L P purchased a new stake in shares of Genomic Health during the second quarter worth about $116,000. Sun Life Financial INC acquired a new stake in shares of Genomic Health during the second quarter worth about $122,000. SG Americas Securities LLC acquired a new stake in shares of Genomic Health during the second quarter worth about $162,000. Pacer Advisors Inc. acquired a new stake in shares of Genomic Health during the third quarter worth about $171,000. Finally, Trexquant Investment LP acquired a new stake in shares of Genomic Health during the third quarter worth about $202,000. Institutional investors and hedge funds own 90.84% of the company’s stock.

GHDX stock opened at $75.76 on Monday. The stock has a market capitalization of $2.85 billion, a P/E ratio of 7,576.00 and a beta of 0.44. Genomic Health has a 1-year low of $26.54 and a 1-year high of $92.18.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Featured Article: Marijuana Stocks Future Looks Bright

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.